Anti-CD5 CAR T Cells for Relapsed/Refractory T Cell Malignancies

Phase 1, open-label, single-arm trial of anti-CD5 CAR T cells in t-cell acute lymphoblastic leukemia (T-ALL) and T-cell non-Hodgkin lymphoma, sponsored by iCell Gene Therapeutics. Primary endpoint: Number of adverse events after anti-CD5 CAR T cells cell infusion at 2 years. Status: unknown.